234 results about "Steroid" patented technology

The present application is applicable to the field of medical devices, and discloses a liquid chromatography-mass spectrometry apparatus and a control method for the liquid chromatography-mass spectrometry apparatus. The liquid chromatography-mass spectrometry apparatus comprises a sample storage device, a pretreatment device, a chromatography device, a mass spectrometry detection device, and a controller. The chromatography device comprises a test solution preparation channel, a test solution transfer assembly, a liquid phase fluid delivery assembly, and a chromatography column. An operating pressure outputted by the liquid phase fluid delivery assembly is less than or equal to 20 MPa. The length of the chromatography column is greater than or equal to 3 mm and less than or equal to 35 mm. A sample comprises a target substance to be measured, and the target substance to be measured comprises at least one of vitamin D, a steroid hormone, and a catecholamine. The present application reduces costs of the liquid chromatography-mass spectrometry apparatus.

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The invention discloses a preparation method of salt-tolerant methanogen liquid for treating high-salt steroid pharmaceutical wastewater, and belongs to the technical field of anaerobic digestion treatment of high-salt pharmaceutical wastewater. According to the technology, the salt-tolerant methanogenic flora is domesticated and enriched through acetic acid and high salt dual stress, and then the salt-tolerant methanogenic bacterial liquid is prepared through passage enrichment, so that a salt-tolerant methanogenic strain is provided for biologically enhancing the anaerobic treatment performance of the high-salt steroid pharmaceutical wastewater, the COD (Chemical Oxygen Demand) removal efficiency and methanogenic efficiency of the high-salt steroid pharmaceutical wastewater are effectively improved, and the method is suitable for industrial production. The conversion of VFAs is accelerated, so that a rapid, low-cost and high-efficiency treatment method can be provided for efficient anaerobic treatment of high-salt steroid pharmaceutical wastewater.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses a non-specific peroxidase HecUPO derived from Hypoxylon sp. (strain EC38), wherein the amino acid sequence of the non-specific peroxidase HecUPO is as shown in SEQ ID NO: 1. The enzyme can efficiently catalyze testosterone to generate 16 alpha-hydroxylation reaction to generate C16 alpha-hydroxytestosterone, the conversion rate reaches 70%, the separation yield reaches 82%, no by-product is generated, and the C16 alpha-hydroxytestosterone has excellent regioselectivity. The invention also discloses a gene for coding the HecUPO, a recombinant plasmid pPICZA-HecUPO containing the gene, a recombinant pichia pastoris engineering bacterium and an application of the recombinant pichia pastoris engineering bacterium in steroid hydroxylation. The non-specific peroxidase HecUPO disclosed by the invention has the advantages of being high in catalytic efficiency, specific in regioselectivity, simple in reaction system, green, environmentally friendly and the like, and a new enzymology resource is provided for fixed-point hydroxylation modification of steroid drugs.

The invention discloses a compound grease feed additive for improving breeding quality of channa maculata and application. The method comprises the following steps: (1) preparing experimental feed; the method comprises the following steps: respectively preparing an experimental group ARA 1.5 added with 1.5% of arachidonic acid and an experimental group ARA + PC added with 1.5% of arachidonic acid and 1.5% of phosphatidylcholine; (2) feeding; (3) after the culture experiment is finished, treating and detecting the channa maculata; (4) carrying out an artificial propagation test; (5) carrying out ovarian steroid synthesis related gene expression detection; and (6) carrying out data statistical analysis. By adding arachidonic acid (ARA) and phosphatidylcholine (PC) into the feed, the breeding performance of channa maculata and the quality of fry are improved, and the feed has very important significance for improving the aquatic product efficiency of high-quality fry of channa maculata in aquaculture.

This application relates to bioabsorbable cationic steroidal antimicrobial (CSA) compounds or salts thereof having a structure of formula I, II or III: formula (I), formula (II) or formula (III), wherein R1-R 18 At least one of them (e.g., R) 18 This includes monoglycerides or diglycerides of fatty acids linked by ester bonds, and R1-R 18 At least one of them (e.g., R3, R7, and R) 12 ) is an amino acid linked to the steroid backbone via an ester bond or an amide bond, wherein: R 18 It has the following structure: -R 19 -(C=O)-O-C-CR 20 -CR 21 , where R 19 The radical is omitted or selected from alkyl, alkenyl, ynyl, and aryl, and R 20 and R 21 Independently selected from hydroxyl, alkylcarboxyl, and aminoalkylcarboxyl groups, provided that R 20 and R 21 At least one of them is an alkyl carboxyl group, R3, R7 and R 12 It has the following structure: R 24 R 23 N-R 22 -(C=O)-X-, where R 22 It is a substituted or unsubstituted alkyl group, X is oxygen or nitrogen, and R is... 23 and R 24 It is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl. (I)(II)(III)

The present disclosure generally relates to topical administration compositions for improving topical compositions, the topical administration compositions comprising at least one active agent, at least one phospholipid, and urea. The active agents of the present disclosure comprise a non-steroid anti-inflammatory drug (NSAID). The topical administration composition of the present disclosure improves the solubility of the NSAID. The present disclosure also relates to a method of making the topical compositions of the present disclosure. The topical composition can be used to treat inflammation, arthritis and / or pain, or conditions of signs and symptoms including inflammation, arthritis and / or pain, by topically administering the topical composition to a subject.

Provided in the present invention are a steroid-cationic lipid compound having a structure as shown in formula (I) and the use thereof. The compound can be used in the preparation of a lipid nanoparticle (LNP) for delivering a therapeutic agent and / or a preventive agent. The LNP prepared using the steroid-cationic lipid compound of the present invention has relatively good stability and transfection efficiency. The use of the LNP for delivering a nucleic acid, e.g., an mRNA, can realize efficient and stable delivery of biologically active substances to target cells or organs, and can induce a high level of specific antibody responses and cellular immune responses in experimental animals. Moreover, the compound has better safety.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

Compositions and methods are provided for the prevention of osteonecrosis or osteoporosis associated with corticosteroid administration in an individual. The methods of the disclosure comprise administration of an effective dose of a metformin agent, or a derivative, mimetic or analog thereof in combination with administration of a corticosteroid. The effective dose of metformin agent decreases oxidative stress and restores osteogenic capacity of mesenchymal stem cells exposed to a glucocorticoid.

The application discloses application of a genetic lineage tracing mouse model in regulation of myocardial cell transformation into osteoblasts, and belongs to the technical field of biotechnology.The tracing mouse model is induced to have myocardial calcification through high-dose steroids or myocardial infarction operation, the tracing mouse model expresses a label protein in myocardial cells of mammals, and the label protein expression in the myocardial cells is realized through a Cre / loxP system.The genetic lineage tracing mouse model provided by the application can be used for detecting myocardial cell transformation into osteoblasts, and can also be used for developing or screening drugs capable of preventing myocardial calcification or preparing products for developing or screening the drugs capable of preventing myocardial calcification.

The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclic ring or a 4-12 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; B is any one of the following groups (1), (2) or (3); C is any one of the following groups (1'), (2'), (3') or (4'); G1 is CH2, NH or O; G2 and G3 are independently of each other CH or N; Z is -C(O)-, -SO2-, -C 1‑3 alkyl- or -CH2-C(O)-; L is a bond, -C 1‑7 alkyl- or -C 1‑7 alkenyl-. The compounds of formula (I) are inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The compounds are useful as medicaments for the treatment of steroid receptor, e.g. androgen receptor or estrogen receptor dependent diseases and disorders such as cancer including prostate cancer and estrogen cancer.

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and / or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and / or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.

The application discloses a steroid-indole alkaloid hybrid dimer compound, a preparation method thereof and application of the compound in preparation of an antitumor chemotherapy drug sensitizer, and first prepares the steroid-indole diketopiperazine alkaloid hybrid compound from a fungus Aspergillus sp. EGF15-0-3 rice culture medium. The compound is a new skeleton compound first discovered in nature. It is first discovered that the hybrid compound has Tdp1 inhibitory activity and can be applied as a tyrosine-DNA phosphodiesterase 1 (Tdp1) inhibitor. It is first discovered that the hybrid compound has chemotherapy sensitization activity on a tumor chemotherapy drug topotecan TPT, which provides a drug source molecule and data support for development of a new natural antitumor combination inhibitor, and has important significance for development and utilization of marine Aspergillus sp. fungus resources.

The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABAA receptor regulator in treatment of depression, convulsions, Parkinsonism and nervous system diseases.

Methods, medical systems, and devices for delivering platelet rich plasma, stem cells, exosomes or other extracellular vesicles, growth factors, neuregulins, hormones, extracellular matrix tissue or microvascular tissue fragments allograft, autograft, or xenograft, anti-inflammatories, steroids, and / or other whole, sectioned, particulated, micronized, or otherwise manipulated substances naturally occurring or synthetic that produce, promote, or enhance angiogenesis, reduce inflammation, reduce oxidative stress, promote healing, and / or otherwise reverse neuropathies or improve function of underlying tissues.

The invention relates to a method for simultaneously detecting various steroid hormones in serum, which comprises the following steps: extracting hormones in serum by a liquid-liquid extraction method; a derivatization reagent is added into the extracted hormone, an oximation reaction is carried out, and the derivatization reagent comprises quaternary ammonium oxygen amine; the hormone after oximation reaction is injected into a two-dimensional liquid chromatography-tandem mass spectrometry system for detection, the hormone is enriched on a one-dimensional chromatographic column, and then the enriched hormone is subjected to back flushing and transferred to a two-dimensional chromatographic column for analysis. According to the method, the backwashing transfer two-dimensional liquid chromatography-tandem mass spectrometry and the derivatization reaction are combined, various steroid hormones including progestational hormone and androgen can be detected at the same time, and the method has the advantage of being high in detection sensitivity.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof. In some embodiments, an outcome of the methods of the present technology is increased relative to the same method comprising use of a corticosteroid.

The present invention relates to a method of conferring or increasing resistance to a plant and / or plant material against a fungal pathogen. To this end, the invention focuses on promoting or increasing the production and / or accumulation of Membrane Steroid Binding Protein 1 (MSBP1), fragments or homologues thereof in a plant or plant material as compared to the corresponding wild type plant or plant material. The invention also relates to plants and plant materials having increased resistance to fungal pathogens, as well as materials and methods of producing or using such plants, plant parts or products therefrom.

Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating diabetic macular edema are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and / or supplemental administrations of aflibercept protein.

The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.